The effects and mechanism of alendronate for copd animal model
Publication date: Available online 24 February 2020Source: Respiratory Medicine Case ReportsAuthor(s): Takayasu Ito, Shotaro Okachi, Tadasuke Ikenouchi, Futoshi Ushijima, Takamasa Ohashi, Masahiro Ogawa, Masato Nagahama, Keiko Wakahara, Naozumi HashimotoAbstractA 65-year-old man with chronic respiratory failure caused by chronic obstructive pulmonary disease, had a pulmonary nodule adjacent to the inlet of right B1 and B3. The patient had undergone a surgery for right renal cell carcinoma and colon cancer 6 years prior. We attempted endobronchial ultrasound-guided transbronchial needle aspiration under non-invasive positiv...
Publication date: Available online 24 February 2020Source: Heart &LungAuthor(s): Annie Heiderscheit, Sikandar Khan, Babar Khan, Linda L. Chlan
Condition: Adherence, Treatment Interventions: Device: Nasal High Flow installation; Device: Non Invasive Ventilation; Other: Training session; Other: Education session Sponsors: University Hospital, Grenoble; Icadom; Fisher and Paykel Healthcare Not yet recruiting
ConclusionsThese findings suggest that glycopyrronium, formoterol, and a combination of glycopyrronium, formoterol, and budesonide inhibit HCoV-229E replication partly by inhibiting receptor expression and/or endosomal function and that these drugs modulate infection-induced inflammation in the airway.
Authors: Pelaia C, Vatrella A, Sciacqua A, Terracciano R, Pelaia G Abstract Introduction: The p38 serine-threonine kinases are members of the large family of mitogen-activated protein kinases (MAPK). In particular, p38 MAPK subgroup includes four isoforms (α, β, γ, δ), among which p38α and p38β are mainly involved in inflammatory disorders. Indeed, by activating key transcription factors and by inducing the expression of several cytokines and chemokines, p38α plays a central role in the pathobiology of chronic obstructive pulmonary disease (COPD).Areas covered: This concise r...
Authors: Crisafulli E, Manco A, Torres A Abstract Introduction: In a subset of chronic obstructive pulmonary disease (COPD)patients the course of the disease is complicated by a severe acute exacerbations (AECOPD) that may require hospitalization, at which time negative outcomes may occur up to 30 days after discharge. Several predictors of negative outcomes have been documented.Areas covered: We considered five negative outcomes related to patients hospitalized with AECOPD: treatment failure, non-invasive mechanical ventilation (NIMV) failure, prolonged length of hospital stay (LHS), short-term mortality (≤ 90 ...
Publication date: 9 March 2020Source: Nutrition, Metabolism and Cardiovascular Diseases, Volume 30, Issue 3Author(s): F. Monfrecola, A. Di Gregorio, F. de Blasio, P. Alicante, G. Miracco Berlingieri, F. de Blasio, L. Scalfi
Publication date: 9 March 2020Source: Nutrition, Metabolism and Cardiovascular Diseases, Volume 30, Issue 3Author(s): F. de Blasio, L. Garello, M. Comune, A. Oliva, C. Bucca
Publication date: 9 March 2020Source: Nutrition, Metabolism and Cardiovascular Diseases, Volume 30, Issue 3Author(s): P. Alicante, F. Monfrecola, A. Di Gregorio, F. de Blasio, B. Bellofiore, F. de Blasio, L. Scalfi
ConclusionsThis large observational study based on claims data reliably identified subjects with COPD treated with open TT and their burden on the NHS. Moreover, it could describe the real clinical management of the open TT, before the marketing of the fixed one. These findings are useful for health policymakers in order to promote the appropriate utilization of both currently marketed and future therapies.
More News: Chronic Obstructive Pulmonary